Vikas Goyal is a biotech entrepreneur and investor, with a particular focus on corporate strategy, capital formation, and corporate partnerships for early-stage therapeutics companies.
Most recently, Vikas was SVP of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, then joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Prior to Pandion, Vikas worked as an investor at SR One, at the time the corporate venture capital arm of GlaxoSmithKline, where he started as an intern while attending Wharton. During his time at SR One, Vikas invested in and served on the boards of nearly 20 early-stage biotech companies including Morphic Therapeutics (Nasdaq: MORF), River Vision Development (acquired by Horizon), Nimbus Therapeutics, Turning Point (acquired by BMS), Spero Therapeutics (Nasdaq: SPRO) and Pandion. Earlier in his career, Vikas was a Consultant at McKinsey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals.
Vikas earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in neurobiology from Harvard University. He is a member of the Kauffman Fellows Society. Vikas lives in the Boston area with his wife Humaira Merchant (Wharton HCMG 2011) and their two daughters.
Contact Vikas at:
[email protected]